ImmuPharma remain focussed on achieving full regulatory approval of Lupuzor with US partner Avion

ImmuPharma plc (LON:IMM), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2019.

Key Highlights (including post Period review)

·    Stable financial performance over the Period

o Cash balance of £1.4 million (31 December 2018:  £4.9 million)

o Loss for the period of £6.1 million (31 December 2018:  £7.2 million)

o Research and development expenses of £2.7 million (31 December 2018: £4.7 million)

o Administrative expenses of £1.8 million (31 December 2018: £1.7 million)

o Share based expense of £2 million (31 December 2018: £1.8 million)

o Basic and diluted loss per share of 3.99p (31 December 2018: 5.19p)

o 2 successful fundraisings, completed in June 2019 and March 2020, securing in total approximately £4.2 million spread over 24 months

·    Dual listing on Euronext Growth Brussels in December 2019

 ‘Autoimmunity’: Lupuzor™

·      Open label extension study – following completion of Lupuzor‘s Phase III trial, an open label extension study undertaken. Analysis of results announced on 28 June 2019

o  62 eligible patients enrolled throughout the US/EU completing 24-week treatment period

o  Primary endpoint successfully achieved confirming safety profile of Lupuzor™

o  No ‘serious adverse events’ related to Lupuzor™ reported

o  Insights into the Phase III data allow optimised Lupuzor™ phase III design to progress

·      Licence and development agreement signed in November 2019 with Avion Pharmaceuticals

o Exclusive rights for US with Avion

o Avion to fund new ‘optimized’ international Phase III trial, up to $25m

o Milestones up to $70m & tiered double-digit royalties up to 17%

o Data from Phase III trial allows approvals in key ex-US markets

o Avion to explore peptide’s potential in other auto-immune diseases for US market

o Discussions continue with potential partners for Lupuzor™ outside of US in key territories

·      Post review period

o Avion strengthened advisory team for Lupuzor™ Phase III trial, including collaboration with leading lupus patient group and formation of KOLs – all senior respected consultants within lupus and autoimmune community in US/EU

·      Proof of Concept study planned for Lupuzor™ in CIDP patients – potential Orphan Drug designation

Other program developments: Nucant and Peptide program combined to form Ureka Pharma SAS

·      Three therapy areas: Cancer, Metabolism and (new) Anti-Infectives (Anti-Viral, Anti-Bacterial, Anti-Fungal) – these programs include:

o Anti-Infective: new BioAMP-B (Anti-Fungal) product for lung infections

o Metabolism: new BioGlucagon product – rescue therapy for low sugar events in diabetes

o All programs provide future partnering opportunities

·      Incanthera plc oncology specialist in which ImmuPharma retains 11.9% shareholding, listed on Aquis Stock Exchange (“AQSE”, formerly NEX Exchange) in February 2020

Commenting on the statement and outlook Tim McCarthy, Chairman, said: “The Board has been focused on delivering a business strategy, which provides the optimum route forward for ImmuPharma and its shareholders, based on its current assets, knowhow, collaborations and funding.  In the medium term, we remain focussed on achieving the full regulatory approval of Lupuzor™ in conjunction with our US partner, Avion, which we believe has the potential to be a ground breaking drug for lupus patients with blockbuster potential in commercial terms. Both companies are focused on expediting Lupuzor™ into a new optimised international Phase III study. Avion’s strengthening of its team of advisors to include a collaboration with a leading lupus patient group and the formation of KOLs, all of whom are senior respected consultants within the lupus and autoimmune community in the US and Europe, only enhances this strategy. In parallel, discussions are continuing with a number of potential commercial partners for Lupuzor™ outside of the US.

“Within the P140 Lupuzor™ platform and having confidence in the data gained from the lupus trials already completed, we can see real opportunities by expanding the disease targets and are now focussing our efforts on a Proof of Concept study in CIDP patients.

“In also broadening our R&D programs we are excited by the potential of our anti-fungal Bio-AMP-B therapy and our new BioGlucagon program, both have the potential of progressing quickly through initial bio-equivalence trials whilst in parallel opening up discussions for potential partnering opportunities. These initiatives continuing to create further opportunities in the medium to long term to enhance shareholder value.

“We are in a new chapter within ImmuPharma’s history, with the investment thesis for the Company and specifically Lupuzor™ being repositioned and we look forward to providing further updates on progress with shareholders over the next period.

“Lastly, the Board would like to thank its shareholders including Lanstead for their support as well as its staff, corporate and scientific advisers and our partners including Simbec-Orion, CNRS and our new partner for Lupuzor™, Avion, for their continued efforts and collaborative expertise.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    ImmuPharma Major Opportunity Within Lupuzor Unlocked

    ImmuPharma (LON:IMM) announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals, a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas.

    Immupharma Plc

    ImmuPharma licenses lupus drug Lupuzor

    British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals. Avion and ImmuPharma will co-develop Lupuzor, including

    Immupharma Plc

    ImmuPharma Chairman explains why the Avion deal is so significant

    ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights of the deal, provides background on Avion,

    Immupharma Plc

    ImmuPharma to present at Biotech Showcase™ 2020

    ImmuPharma (LON:IMM), a specialist drug discovery and development company, has announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13-15 January 2020, at the Hilton, San Francisco Union Square. Dr

    Immupharma Plc

    Selena Gomez’s Lupus Flare Up at AMA’s

    Selena Gomez took to the American Music Awards (AMAs) stage for the first time in two years on Sunday night to perform two new tracks, ‘Lose You To Love Me’ and ‘Look At Her Now’. However, the

    Immupharma Plc

    Selena Gomez opens up on body-shaming comments

    Selena Gomez has admitted to struggling after being “attacked” for gaining weight following her lupus diagnosis. The chart-topping singer, 27, was diagnosed with lupus in 2015 and later underwent a kidney transplant due to complications from

    Immupharma Plc

    Lupus flare-ups could be linked to environmental factors

    Researchers have found that alteration in the environment and atomospheric factors could be associated with organ specific flare-ups of lupus among patients diagnosed with Systemic Lupus Erythematosus (SLE). The study results were presented at the 2019 ACR/ARP Annual Meeting.

    Immupharma Plc

    Lupus: the ‘invisible’ disease

    “Lupus mimics other diseases in your body and the community still doesn’t understand what it is,” says Daniella Djan who is living with the condition. Djan’s life changed irrevocably when she was 18-years-old and diagnosed with

    Immupharma Plc

    Managing Fatigue in Lupus

    Fatigue can be described as a feeling of weariness that is more extreme than simple tiredness. It often includes a lack of both physical and mental (or emotional) energy and motivation. The fatigue that many patients

    Immupharma Plc

    Look At Her Now: Selena Gomez

    Selena Gomez is back, and fans couldn’t be happier. It’s a triumphant return for Selena, who has suffered through health issues and break-ups over the past two years – but nothing can hold this girl down.

    Immupharma Plc

    Living with Lupus

    Another day, another torment. The same will follow the next day — the excruciating pain, inexplicable fatigue, and never-ending drowsiness. This is life with lupus, a rare, chronic autoimmune condition where the body’s immune system starts

    Immupharma Plc

    Lupus: 9 Early Signs that Mean You Have It

    Lupus is a serious disease which causes intense inflammation along with a variety of other symptoms. Each sufferer’s symptoms are quite different. Here, MusicSnake Magazine put together a list of 9 Early Signs that may mean you have lupus. Number One:

    Immupharma Plc

    Lupus and Celiac Disease: What Pharmacists Need to Know

    According to the Lupus Foundation of America, approximately 5 million people globally are affected by lupus and about 16,000 new cases are reported annually. Lupus occurs when the body’s immune system attacks the tissues and organs, which